Breast cancer spreads most often during sleep, unexpected findings from researchers indicates

Research findings have unearthed "potential implications for the timing of biopsy and treatment of metastasis-prone cancers."

That's one conclusion from the authors of a study published some time ago in the journal Nature that decided "the metastatic spread of breast cancer occurs predominantly during sleep."

The findings, according to a story by Megan Brooks online in Medscape Medical News, were "unexpected."

Nicola Aceto, PhD

Brooks quotes Nicola Aceto, PhD and professor of molecular oncology at the Swiss Federal Institute of Technology  (ETH) Zurich, Switzerland, as saying, "This has not been shown before [and] we were surprised, indeed."

Harrison Ball, a PhD candidate, and Sunitha Nagrath, PhD, of the University of Michigan, Ann Arbor, also are quoted, to the effect that "this finding is astounding."

In addition, Brooks' piece quotes Dr. Marlene Myers, clinical professor of medicine at NYU Langone's Perlmutter Cancer Center in New York City, regarding clinical implications: "The most obvious is that the time of day [that] treatment is administered may influence efficacy."

She adds, however, that the benefits of treatment someone at night would need to be weighed against the downsides of interrupting a person's normal sleep-wake cycle. 

More information on research can be found in "Rollercoaster: How a man can survive a partner's breast cancer," a VitalityPress book that I, Woody Weingarten, aimed at male caregivers.

Clinical trial of new drug for metastatic breast cancer patient shows 'unheard of' survival rates

A new clinical breast cancer drug trial has resulted in "unheard of" survival rates.

According to a recent story by Gina Kolata in The New York Times, for some patients with metastatic tumors that were not significantly affected by other forms of chemotherapy, the treatment halted their cancer's growth.

The findings of a new study, published in the New England Journal of Medicine, might "change how medicine [is] practiced," the article indicates.

Dr. Eric Winer, who was not involved in the study but who is director of the Yale Cancer Center and head of the American Society of Clinical Oncology, is quoted as saying that "this is a new standard of care. It affects a huge number of patients."

The Times piece notes that the new treatment, using an experimental drug (trastuzumab deruxtecan, sold as Enhehru) "that targeted cancer cells with laser like precision" was "stunningly successful, slowing tumor growth and extending life to an extent rarely seen with advanced cancers."

The trial, which focused on a mutant protein known as HER2, involved 557 patients. Tumors in those who took the experimental drug stopped growing for about 10 months, twice the length of those who took only standard chemotherapy. Those patients survived for almost two years, compared to less than a year and a half for those who received standard chemo.

Dr. Halle Moore

"It is unheard of for chemotherapy trials in metastatic breast cancer to improve survival in patients by six months," the story quotes Dr. Halle Moore, director of breast cancer oncology at the Cleveland Clinic, as saying.

Dr. Susan Domchek, a breast cancer specialist at the University of Pennsylvania's Abramson Cancer Center, also is quoted to the effect that she plans to see — even before the Food and Drug Administration approves the drug, which has a wholesale price of about $14,000 every three weeks — if the data from the study will be sufficient to convince insurers to approve it.

More information about successful clinical trials can be found in "Rollercoaster: How a man can survive his partner's breast cancer," a VitalityPress book that I, Woody Weingarten, aimed at male caregivers.